Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 64, Issue 17, 1799-1807
Copyright © 2007 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rao, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, K. V.
American Journal of Health-System Pharmacy, Vol. 64, Issue 17, 1799-1807
Copyright © 2007. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00


Clinical Review

Lenalidomide in the treatment of multiple myeloma

Kamakshi V. Rao

KAMAKSHI V. RAO, PHARM.D., BCOP, is Hematology/Oncology Clinical Specialist, Department of Pharmacy, University of North Carolina Hospitals and Clinics, 101 Manning Drive, CB 7600, Chapel Hill, NC 27514 (kvrao{at}unch.unc.edu).


Purpose. The pharmacology, clinical use, adverse effects, dosage and administration, and cost of lenalidomide in the treatment of multiple myeloma (MM) are reviewed.

Summary. Lenalidomide is an analogue of thalidomide and has been shown to be more potent than thalidomide in the stimulation of T-cell, interleukin-2, and interferon-{gamma} production. Both drugs have direct cytotoxic effects on myeloma cells and are capable of inducing apoptosis. They are also capable of reducing angiogenesis through the inhibition of the secretion of vascular endothelial growth factor (VEGF). Inhibition of VEGF leads to alterations in the microvasculature of the bone marrow environment and inhibits myeloma cell growth and proliferation. Unlike thalidomide, lenalidomide has almost no sedative or constipative properties and induces only minimal neurotoxicity; however, there is concern about lenalidomide’s teratogenic potential. Phase I, II, and III trials have been carried out with lenalidomide in patients with relapsed or refractory MM, and the drug has shown impressive response rates in relapsed disease. The combination of lenalidomide and dexamethasone has shown superior patient survival. Lenalidomide’s efficacy in newly diagnosed MM is currently being studied. Neutropenia and thrombocytopenia were found to be the most common grade 3 or higher toxicities. Rates of these toxicities varied among trials and may have been affected by the setting in which lenalidomide was used (i.e., relapsed or refractory disease versus newly diagnosed MM).

Conclusion. Lenalidomide, a thalidomide analogue, has produced good results when used with dexamethasone in patients with relapsed or refractory MM. Lenalidomide is associated with hematologic toxicities, and participation in a restricted-distribution program is required of prescribers, pharmacies, and patients because of the drug’s teratogenic potential.

Index terms: Antineoplastic agents; Combined therapy; Costs; Dexamethasone; Dosage; Drug administration; Lenalidomide; Mechanism of action; Multiple myeloma; Pregnancy; Steroids, cortico-; Teratogenicity

 



This article has been cited by other articles:


Home page
BloodHome page
P. Richardson, S. Jagannath, M. Hussein, J. Berenson, S. Singhal, D. Irwin, S. F. Williams, W. Bensinger, A. Z. Badros, R. Vescio, et al.
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Blood, July 23, 2009; 114(4): 772 - 778.
[Abstract] [Full Text] [PDF]


Home page
NDT PlusHome page
I. G. Glezerman, T. Kewalramani, and K. Jhaveri
Reversible Fanconi syndrome due to lenalidomide
NDT Plus, August 1, 2008; 1(4): 215 - 217.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Health-System Pharmacists.
Advertisement